Trials6 min read
Semaglutide Cuts Heart Risk 29% More Than Tirzepatide
New STEER study: semaglutide cut major cardiac events 29% more than tirzepatide in obesity patients without diabetes. What it means for stack choice.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Vendors2 min read
Dynamic Peptide Review: Not Recommended
Dynamic Peptide is no longer on our recommended vendor list. What that means if you were planning to order, and the vendors we point buyers to now.
Vendors2 min read
BioLongevity Labs Review
BioLongevity Labs is a US research-peptide vendor focused on specialty and longevity compounds. How they operate and the vendors we track side by side.
Vendors5 min read
Best Peptide Vendors 2026: COA-Tested Sources Ranked
5 vendors compared on third-party COA, price, and shipping reliability. Scorecard with $/mg comparison and which ones don't pass our test.
Trials7 min read
Semaglutide Reverses Knee Cartilage: New Study
May 2026 research: semaglutide reverses knee cartilage damage independent of weight loss. MRI showed 17% thicker cartilage. What it means.
Trials6 min read
Retatrutide Tingling: 20.9% Hit by Dysesthesia
TRIUMPH-4 Phase 3 found 1 in 5 patients on retatrutide 12mg develop dysesthesia. What it feels like, why it happens, and how to manage it without quitting.
Industry5 min read
The Peptide Media Panic: What They Got Wrong
The New Yorker, NBC, and STAT ran peptide scare stories in April 2026. Here is what they nailed, what they missed, and how to actually stay safe.
Regulatory4 min read
Orforglipron Approved: First Oral GLP-1 Pill
FDA approved orforglipron April 1 at $149/mo -- but compounded semaglutide still beats it on weight loss. Full cost and efficacy comparison inside.
Industry8 min read
GLP-1 Not Needed for Weight Loss? GIP/Glucagon
DiMarchi, who pioneered GLP-1 obesity drugs, now says GIP/glucagon alone may match GLP-1 — without nausea. What it means for retatrutide buyers.
Industry4 min read
GLP-1 Genetic Resistance: What to Do If You're a Non-Responder
10% of people carry gene variants that reduce GLP-1 drug response. How to tell if you're one, what the research says, and which alternatives actually work.
Trials8 min read
GLP-1 for Alzheimer's: 2026 Trial Results (Mixed)
Semaglutide EVOKE trial missed its primary endpoint. Liraglutide ELAD showed 50% less brain volume loss. What the 2026 data means for GLP-1 peptide buyers.
Industry10 min read
GHRH vs GHRP: Different Receptors Guide
They both boost GH but through completely different pathways. Mechanisms, stacking logic, and which to use when.
Regulatory11 min read
14 Peptides Legal Again: FDA Reclassification Explained
RFK Jr. announced 14 of 19 banned peptides return to Category 1. Which ones, what it means for compounding, and 5 that stay restricted.
Regulatory8 min read
Dihexa: Off FDA Category 2, But Is It Legit?
Dihexa dropped off FDA Category 2 April 22. But the foundational research came from a company that paid $4M for misconduct. Here's the full picture.
Regulatory6 min read
GLP-1 Compounding Crackdown: Your Options Now
FDA sent 30 warning letters to telehealth GLP-1 compounders. Here's what's still legal, what changed, and where to source semaglutide and tirzepatide now.
Vendors9 min read
Ascension Peptides vs EZ Peptides
50% off vs 10% off — which vendor wins on price, catalog, and COAs? We ran the $/mg math on BPC-157, retatrutide, tirzepatide, and more.
Pricing10 min read
Peptides Under $50/vial: 12 Picks
12 peptides priced under $50/vial with real vendor links — healing, cognitive, sexual, metabolic. $/mg shown for every pick so you can buy smart.
Pricing9 min read
Peptide Stacks Under $200/Month
4 complete peptide protocols under $200/month — fat loss, healing, anti-aging, sleep. Per-peptide cost math, vendor picks, and which vial to buy.